Alnylam Pharmaceuticals
ALNY
#549
Rank
S$56.81 B
Marketcap
S$430.05
Share price
-2.52%
Change (1 day)
15.85%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): S$0.11

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is S$0.11. In 2023 the company made an earnings per share (EPS) of S-$4.49 an increase over its 2022 EPS that were of S-$11.82.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$0.11
2023S-$4.49-62%
2022S-$11.8229.03%
2021S-$9.16-3.36%
2020S-$9.48-8.48%
2019S-$10.357.67%
2018S-$9.6239.74%
2017S-$6.8812.94%
2016S-$6.0938.84%
2015S-$4.39-32.88%
2014S-$6.54259.44%
2013S-$1.82-31.25%
2012S-$2.65

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
S$9.36 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$4.71 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
S$55.26 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
S-$3.49-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
S-$0.93-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
S-$0.31-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$0.80 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
S-$1.59-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA